125 related articles for article (PubMed ID: 18025917)
1. Genetic testing for melanoma predisposition: current challenges.
Gerstenblith MR; Goldstein AM; Tucker MA; Fraser MC
Cancer Nurs; 2007; 30(6):452-9; quiz 462-3. PubMed ID: 18025917
[TBL] [Abstract][Full Text] [Related]
2. High- and low-penetrance cutaneous melanoma susceptibility genes.
Fargnoli MC; Argenziano G; Zalaudek I; Peris K
Expert Rev Anticancer Ther; 2006 May; 6(5):657-70. PubMed ID: 16759158
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetics of familial cutaneous melanoma.
Haluska FG; Hodi FS
J Clin Oncol; 1998 Feb; 16(2):670-82. PubMed ID: 9469357
[TBL] [Abstract][Full Text] [Related]
5. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
[TBL] [Abstract][Full Text] [Related]
7. Genetic variations of patients with familial or multiple melanoma in Southern Brazil.
Grazziotin TC; Rey MC; Bica CG; Pinto LA; Bonamigo RR; Puig-Butille JA; Cuellar F; Puig S
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e179-85. PubMed ID: 22621339
[TBL] [Abstract][Full Text] [Related]
8. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
11. Clinical germline genetic testing for melanoma.
Hansen CB; Wadge LM; Lowstuter K; Boucher K; Leachman SA
Lancet Oncol; 2004 May; 5(5):314-9. PubMed ID: 15120668
[TBL] [Abstract][Full Text] [Related]
12. CDKN2A mutations in melanoma families from Uruguay.
Larre Borges A; Cuéllar F; Puig-Butillé JA; Scarone M; Delgado L; Badenas C; Milà M; Malvehy J; Barquet V; Núñez J; Laporte M; Fernández G; Levrero P; Martínez-Asuaga M; Puig S
Br J Dermatol; 2009 Sep; 161(3):536-41. PubMed ID: 19523171
[TBL] [Abstract][Full Text] [Related]
13. Management of familial melanoma.
Bishop JN; Harland M; Randerson-Moor J; Bishop DT
Lancet Oncol; 2007 Jan; 8(1):46-54. PubMed ID: 17196510
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
15. Genetics of melanoma predisposition.
Hayward NK
Oncogene; 2003 May; 22(20):3053-62. PubMed ID: 12789280
[TBL] [Abstract][Full Text] [Related]
16. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
17. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
[TBL] [Abstract][Full Text] [Related]
18. Genetics in melanoma.
Stahl S; Bar-Meir E; Friedman E; Regev E; Orenstein A; Winkler E
Isr Med Assoc J; 2004 Dec; 6(12):774-7. PubMed ID: 15609895
[TBL] [Abstract][Full Text] [Related]
19. [Genetic counseling and DNA testing in patients with increased risks for malignant melanoma].
Itin PH; Fistarol SK
Ther Umsch; 2003 Aug; 60(8):469-72. PubMed ID: 14502854
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for genetic testing in patients with melanoma?
Kefford RF; Mann GJ
Curr Opin Oncol; 2003 Mar; 15(2):157-61. PubMed ID: 12601281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
